Effects of Yiqi Huayu Jiedu Prescription on MHCC97-H Migration Ability and Expressions of Chemokines CXCL12, CXCR4 and CXCR7
10.3969/j.issn.1005-5304.2018.07.010
- VernacularTitle:益气化瘀解毒方对人肝癌细胞MHCC97-H迁移能力及趋化因子CXCL12、CXCR4、CXCR7表达的影响
- Author:
Wen-Hui GAO
1
;
Pu-Hua ZENG
;
Hui-Yong HUANG
;
Shu-Lin YE
;
Min-Qiu PAN
;
Fang ZHOU
;
Wei LI
;
Dan LIU
Author Information
1. 湖南中医药大学
- Keywords:
Yiqi Huayu Jiedu Prescription;
Sorafenib;
MHCC97-H;
chemokines
- From:
Chinese Journal of Information on Traditional Chinese Medicine
2018;25(7):41-43
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the effects of Yiqi Huayu Jiedu Prescription on the migration ability of MHCC97-H and the expressions of CXCL12, CXCR4 and CXCR7; To discuss its relevant mechanism of action. Methods Setting Sorafenib as a positive control, CCK-8 method was used for determining the effects of Yiqi Huayu Jiedu Prescription on the cell proliferation of MHCC97-H and the optimum concentration. Scratch assay was used to observe the migration ability of MHCC97-H. The protein expressions of CXCL12, CXCR4 and CXCR7 were detected by Western blot after 24 h of medicine intervention. Results Yiqi Huayu Jiedu Prescription and Sorafenib can inhibit the cell proliferation of MHCC97-H , and the inhibitory concentration was 0.095 g/mL and 10 μmol/mL at 24 hours. Yiqi Huayu Jiedu Prescription can inhibit migration ability of MHCC97-H. The protein expressions of CXCL12, CXCR4 and CXCR7 in hepatocellular carcinoma cells decreased after the action of Yiqi Huayu Jiedu Prescription. Conclusion Yiqi Huayu Jiedu Prescription can inhibit MHCC97-H cell proliferation and migration, which may be realized by down-regulating chemokine axis of CXCL12/CXCR4/CXCR7.
